Roche to Present New Data at ASCO 2026 on Giredestrant’s Potential in Early Breast Cancer Treatment
Roche is set to present data from nine medicines at the ASCO 2026 Annual Meeting, focusing on the investigational drug giredestrant, an oral selective estrogen receptor degrader. The data underscore giredestrant’s potential as a standard of care in early breast cancer treatment, specifically for ER-positive, HER2-negative cases. The company aims to redefine treatment paradigms and showcase advancements in HER2-positive breast cancer as well.
Basel, 19 May 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held 29 May to 2 June in Chicago.